Diabetes patients with CRD used less fast-acting (10.0% vs. 12.4%, 2018, p <.0001), less long-acting (25.2% vs. 29.8%, 2018, p <.0001), more premixed (59.9% vs. 53.8%, 2018, p <.0001), and more intermediated-acting insulin (12.7% vs. 12.3%, 2018, p = .0061). This evidence concerns the gene INS and diabetes mellitus.